Current and future treatments for Alzheimer's disease.
Citations
395 citations
Cites background from "Current and future treatments for A..."
...At the advanced stages of the disease i.e. mild-to-severe symptomatic AD, management is mostly symptomatic relief (Aaseth et al., 2016; Folch et al., 2016; Livingston et al., 2017; Yiannopoulou & Papageorgiou, 2013)....
[...]
313 citations
262 citations
243 citations
203 citations
Cites background from "Current and future treatments for A..."
...…and galantamine) do so by enhancing the cholinergic neurotransmission, whereas memantine (a non-competitive antagonist of N-methyl-Daspartate receptors, NMDAR) is considered to have protective activity against glutamateinduced excitotoxic neuronal death (Yiannopoulou and Papageorgiou, 2013)....
[...]
...Cholinomimetics (tacrine, rivastigmine, donepezil, and galantamine) do so by enhancing the cholinergic neurotransmission, whereas memantine (a non-competitive antagonist of Nmethyl-D-aspartate receptors, NMDAR) is considered to have protective activity against glutamate-induced excitotoxic neuronal death (Yiannopoulou and Papageorgiou, 2013)....
[...]
References
5,671 citations
"Current and future treatments for A..." refers background in this paper
...It has been recognized that, to modify AD, which has recently been redefined to have presymptomatic and symptomatic phases, one must attempt to treat patients when neuronal dysfunction is far from full blown and largely irreversible [Dubois et al. 2010; Sperling et al. 2011]....
[...]
5,318 citations
"Current and future treatments for A..." refers background in this paper
...…disease process, including loss of acetylcholine neurons, loss of enzymatic function for acetylcholine synthesis and degradation, resulting in memory loss and deterioration of other cognitive and noncognitive functions such as neuropsychiatric symptoms [Bartus et al. 1982; Cummings and Back, 1998]....
[...]
...Cholinesterase inhibitors The cholinergic hypothesis of AD concludes that cholinergic systems in the basal forebrain are affected early in the disease process, including loss of acetylcholine neurons, loss of enzymatic function for acetylcholine synthesis and degradation, resulting in memory loss and deterioration of other cognitive and noncognitive functions such as neuropsychiatric symptoms [Bartus et al. 1982; Cummings and Back, 1998]....
[...]
4,891 citations
1,776 citations
"Current and future treatments for A..." refers background in this paper
...It has been recognized that, to modify AD, which has recently been redefined to have presymptomatic and symptomatic phases, one must attempt to treat patients when neuronal dysfunction is far from full blown and largely irreversible [Dubois et al. 2010; Sperling et al. 2011]....
[...]
1,637 citations
"Current and future treatments for A..." refers background in this paper
...Epidemiological studies have indicated that patients treated for cardiovascular disease with cholesterol-lowering therapy (statins) showed a decreased prevalence of AD [Jick et al. 2000]....
[...]